RGEN — REPLIGEN CORP

Nasdaq · Health Care · Biotechnology · CIK 730272 ·
Last close
$115.19
Market Cap
$6.50B
52W High
$141.46
52W Low
$100.99
ADV30
1,280,493
Next earnings
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026
Dec 2025 197,913,000 103,831,000 16,348,000 13,287,000 2,949,699,000 566,021,000 843,570,000
Sep 2025 188,805,000 100,515,000 12,677,000 14,911,000 2,923,711,000 748,747,000 840,624,000
Jun 2025 182,366,000 91,142,000 5,957,000 14,866,000 2,901,627,000 708,855,000 839,886,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$117,417,000
Investing CF
$-298,474,000
Financing CF
$-15,205,000
CapEx
$-25,730,000
Dividends Paid
Buybacks
EPS Diluted TTM
$0.90
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$456,248,000
Inventory
$170,458,000
Receivables
$158,587,000
ST Investments
$201,607,000
EBIT TTM
$70,703,000
Pretax Income TTM
$54,440,000
Interest Exp TTM
$16,263,000
Analysts
18

Yahoo Snapshot (yfinance, live)

Total Revenue
$763,339,008
EBITDA
$134,236,992
Free Cash Flow
$68,723,376
Enterprise Value
$6,393,363,456
Total Cash
$784,531,008
Total Debt
$687,619,968
Shares Out
56,407,740
Trailing EPS
$0.91
Book Value
$37.33
ROE
2.5%
ROA
1.2%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 738,256,000 41,560,000 48,894,000 2,949,699,000 843,570,000 117,417,000
Dec 2024 634,439,000 -31,923,000 -25,514,000 2,829,666,000 856,948,000 175,394,000
Dec 2023 632,362,000 17,134,000 35,596,000 2,831,185,000 866,340,000 113,918,000
Dec 2022 801,536,000 195,941,000 185,959,000 2,531,600,000 620,900,000 172,083,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$2.55

Peers — same industry

TickerNameMarket CapLastDaily %
KYMR Kymera Therapeutics, Inc. $6.64B $80.77
SRRK Scholar Rock Holding Corp $6.17B $51.51
IMVT Immunovant, Inc. $6.95B $33.83
PCVX Vaxcyte, Inc. $7.24B $50.11
QGEN QIAGEN N.V. $7.33B $35.54

News headlines (Yahoo Finance, 1h cache)

3 Out-of-Favor Stocks We Keep Off Our Radar
2026-05-23 09:24 · Yahoo
3 Stocks That May Be Trading Below Their Estimated Value In May 2026
2026-05-22 11:38 · Yahoo
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
2026-05-22 11:30 · Yahoo
Q1 Rundown: Repligen (NASDAQ:RGEN) Vs Other Drug Development Inputs & Services Stocks
2026-05-20 23:24 · Yahoo
Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report
2026-05-20 11:30 · Yahoo
Why Repligen (RGEN) Stock Is Trading Up Today
2026-05-19 15:00 · Yahoo
1 Growth Stock with Explosive Upside and 2 Facing Headwinds
2026-05-19 12:28 · Yahoo
Repligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To Know
2026-05-17 09:56 · Yahoo
3 Small-Cap Stocks We Steer Clear Of
2026-05-15 13:08 · Yahoo
5 Revealing Analyst Questions From Repligen’s Q1 Earnings Call
2026-05-15 09:48 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.